MAMyhailo A. Artemchuk

Myhailo A. Artemchuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Myhailo A. Artemchuk has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyperhomocysteinemia: a modern view of the problem (literature review)

    by M. B. Lutsyuk, N. V. Zaichko, D. O. Nekrut, M. A. Artemchuk, K. P. Postovitenko

    Annotation. The purpose of the work was to systematize modern scientific information on the etiology and mechanisms of development of hypohomocysteinemia, to argue its possible role in pathology and the expediency of correcting a low level of homocysteine. The analysis and generalization of the results of scientific research for the years 2012-2023, selected on the basis of information search in the scientometric databases Scopus, Web of Science, PubMed, MEDLINE, Google Scholar, was carried out. Hypohomocysteinaemia is a metabolic disorder that occurs in 0.5-1% of the population and is genetically determined or acquired. Recognised causes of hypohomocysteinaemia include a mutation of the NFE2L2 gene, and acquired causes include high doses of vitamins and trace elements with hypohomocysteinemic effects, primarily vitamins B6, B9, B12. Hypohomocysteinaemia can be caused by factors such as nutritional deficiency of methionine, N-acetylcysteine, insulin, pregnancy, and coronavirus disease, but this disorder is often idiopathic. The biochemical mechanisms of hypohomocysteinemia include excessive activation of methyltransferase reactions, increased need for homocysteine and cysteine in the face of increased glutathione intake, increased activity of transsulfuration processes involving cystathionine beta-synthase, separation of homocysteine from blood proteins and increased urinary excretion. The clinical significance of hypohomocysteinemia is due to a decrease in numerous physiological functions of homocysteine, which leads to a reduced ability to respond to oxidative stress and certain types of toxins, and increases the risk of developing idiopathic peripheral neuropathy, Parkinson's and Alzheimer’s diseases. There are no special approaches to the prevention and correction of hypohomocysteinaemia, which indicates the prospects for further research into this metabolic phenomenon and the development of new pharmacotherapeutic approaches.

  • Open Access

    The analysis of the range of antihistamines at the pharmaceutical market of Ukraine

    by О. P. Balitska, V. S. Zlahoda, O. D. Haiday, O. D. Blahun, M. A. Artemchuk

    Aim. To analyze the range of antihistamines (AH) at the pharmaceutical market of Ukraine. Materials and methods. The analysis of the range of drugs was carried out in accordance with the State Register of Medicines of Ukraine as of February 2023, the weekly “Apteka” to determine the data of actual sales of AH. Statistical, frequency and graphic methods were used in the analysis. The information was processed using Microsoft Office Excel. Results. As a result of the frequency analysis, it was found that the pharmaceutical market of Ukraine as of February 2023 of AН for systematic use was represented by 170 trade names (TN) and 135 international non-proprietary names (INN). The leaders by INN were Desloratadine (34 TN) and Levocetirizine (26 TN). According to the State Register of Medicines of Ukraine as of February 2023, there were different drug forms, namely: tablets, solutions, drops, syrups, dragees and granules for the preparation of oral suspension. The largest share was AH in the form of tablets (70.59 %), solutions, drops, and syrups accounted for almost the same percentage (10 %, 9,41 %, 8,82 %), and 2 % of AH were registered in the form of dragees. The ratio of AH producing countries at the pharmaceutical market of Ukraine by TN was also determined. It was found that among the dosage forms presented, 62 % were of foreign production. AH of domestic production were 38 %; moreover, the largest market share (19 %) was produced by LLC Pharmaceutical Company “Zdorovye”. According to the results of the official data of weekly “Apteka” on the actual consumption of AH, it was found that AH of the second generation were the most popular both by INN and TN. It is due to their pharmacokinetic properties and the optimal price/effectiveness ratio. Conclusions. Based on the above, we can conclude that the pharmaceutical market of Ukraine is represented by a wide range of AH in various forms of production and various manufacturers. This leads to a wide choice of drugs of this group among the population, pharmaceutical and medical professionals.

  • Open Access

    The ABС-analysis of the consumption of antihistaminic drugs

    by О. P. Balitska, V. S. Zlahoda, Yu. M. Hryhoruk, O. D. Gaiday, O. D. Blahun, M. A. Artemchuk

    Aim. To analyze the demand and consumption of antihistaminic drugs (AHD) at the pharmaceutical market of Ukraine on the example of one of the pharmacies in Vinnytsia. Materials and methods. A pharmacy in Vinnytsia, nomenclature of AHD, retail prices for AHD of the pharmacy under research were studied. The methods of survey, statistical, comparative, as well as ABC analysis were used. Results. As a result of the study, the demand and consumption of AHD were analyzed on the example of one of the pharmacies in Vinnytsia for the period February-April 2021 using the ABC analysis. Nixar, Cetrine 20, L-cet, Dexamethasone, Cetrilev, Aerius, Cetrine 30 were the leading drugs in sales and accounted for 80 % of the total turnover. The total revenue of these funds was UAH 8218,68. Group B included Loratidine, Allerzin, Ergocetal, Claritin, which accounted for 15 % of the total amount of sales. The total revenue of these funds was UAH 1660,18. Such drugs as Cetirizine-TEVA, Suprastin, Allergosan, Tavegil, Ketotifen, and Diphenhydramine were 5 % of the total sales. The total revenue of these funds was UAH 718,43. Conclusions. It has been found that the following AHP are in the greatest demand among the population: Nixar, Cetrine 20, L-cet, Dexamethasone, Cetrilev, Aerius, Cetrine 30. These drugs provide the main income of the pharmacy chain, and pharmacy employees need to ensure 100 % availability of this product name.

  • Open Access

    The assessment of the rationality of the pharmacotherapy of acute respiratory viral infection in the outpatient practice

    by O. P. Balitska, Yu. M. Hryhoruk, M. A. Artemchuk, V. S. Zlahoda V. S.

    Acute respiratory viral infections (ARI) and influenza occupy a leading place in the structure of the overall morbidity of the population in most countries. Aim. To assess the rational prescription of drugs for etiotropic therapy of ARI in the outpatient practice. Materials and methods. The following materials for research were used: case histories; treatment sheets; the Unified clinical protocol of primary care for adults and children “Acute respiratory infections”; data of the State Formulary of Medicines as of January 2021; the Register of wholesale prices; the weekly “Apteka” (Pharmacy). The methods of retrospective, descriptive, frequency, and VEN-analysis were applied. Results. According to the research results, using patient histories, it was found that family doctors prescribed 67 drugs by trade names. For etiotropic therapy, 24 drugs were used; it was 37 % of the total number, and 63 % – for symptomatic therapy. Such drugs as Amizon, Aflubin, Amixin, Resistol, Umkalor were for etiotropic therapy (more than 5 prescriptions). None of these drugs is included in the State Formulary of Medicines and the Unified clinical protocol for the treatment of influenza and SARS. Thus, these drugs are without the proven efficiency, safety and cost-effective use. Conclusions. The study conducted has shown that the drugs prescribed most often do not have an evidence base of efficacy and safety; none of the most frequently prescribed drugs is included in the State Formulary of Medicines and the Unified clinical protocol. A direct relationship between an increase in the number of prescriptions and an increase in price has been proven. Key words: acute respiratory viral infections; influenza; frequency analysis; VEN-analysis; family doctor.


  • Open Access

    Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer

    by Olesya P. Balitska, Tamara A. Germanyuk, Yuliia M. Hryhoruk, Tatiana I. Ivko, Yuliia O. Tomashevska, Vasyl M. Koval, Yuliia M. Polishchuk, Viktoriia V. Hutsol, Myhailo A. Artemchuk

    Aim. The aim of this study is to evaluate the efficiency of proton pump inhibitors in the treatment of gastric and duodenal ulcers as based on literature. Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors analysis. Methods. Descriptive, statistical, retrospective. Results and Conclusion. According to the clinical random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 week repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9±6.2), Pariet + Amoxicillin + Clarythromycin (83±2.6), Kontrolok + Amoxicillin + Clarythromycin (100±1.3), Pultset + Amoxicillin + Clarythromycin (88±4.1), Nolpaza + Amoxicillin + Clarythromycin (72±4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7±3.8), Neksium + Amoxicillin + Clarythromycin (96.1±3.1).


    • 30 March 2006
      • Vol. 77  (4)

    Age-related effects of methionine-enriched diet on plasma homocysteine concentration and methylation of hepatic DNA in rats.

    by I P Pogribny, T V Prizimirska, G I Kulik, M B Lutsiuk, O O Pentiuk, K P Postovitenko, Mihaylo Artemchuk, L A Poirier, V F Chekhun

    In the present study we determined the age-related effect of methionine-enriched diet, a model of hyperhomocysteinemia, on the level of plasma homocysteine and hepatic global DNA methylation in rats. Feeding methionine diet to middle-aged rats for only 14 days resulted in a significant increase in plasma homocysteine level and DNA hypomethylation. In contrast, feeding the methionine-containing diet for 2 weeks to juvenile or post-pubertal animals did not alter the level of plasma homocysteine or hepatic DNA methylation. Supplementation of the methionine-enriched diet with vitamins B6, B12 and folic acid prevented both hepatic DNA hypomethylation and an increase of plasma homocysteine concentration in the middle-aged rats. These findings indicate that the elevated level of plasma homocysteine may be indicative of much broader and deeper alterations in intracellular methylation dysfunction, and suggest that dietary enrichment with B-vitamins is essential for the metabolism of homocysteine, especially in adult animals.